Barring infection: A new CD4-binding peptidomimetic (see ball-and-stick structure; CD4 is shown in green) has been designed and synthesized as an entry inhibitor of the HIV virus. The binding affinity of the peptidomimetic for CD4 is 40 μM, which is 150-fold better than that of the lead peptide NMWQKVGTPL. The mimetic also has a lower molecular weight and a higher proteolytic stability than the lead peptide.
No takes yet. Share an insight, caveat, or question.
Neffe et al. (2004) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: